YOLFTbeta
34

Quratis Inc.

348080 · KQ · Healthcare / Biotechnology

3,530.00KRW-15.00 (-0.42%)

Price History

Full chart

Market Stats

Previous Close3,545.00
Open3,500.00
Day Range3,475.00 – 3,635.00
52-Week Range1,765.00 – 13,378.38
Volume23.39K
Market Cap49.08B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.24
50-Day Avg3,097.14
200-Day Avg6,361.88

About

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Sung-Joon Kim
  • Headquarters143 Medical Complex-gil, Cheongju-si, South Korea, 08375, Korea
  • Websitehttps://www.quratis.com

Leadership

  • Mr. Sung-Joon KimCEO & Director · b. 1974
  • Mr. Donghoon KimExecutive Director · b. 1970
  • Mr. Jin-Hee LeeManaging Director · b. 1969
  • Mr. Hyungki ChoiExecutive Director · b. 1987
  • Mr. JaeHo SonManaging Director · b. 1964
  • Mr. SeokNam DongManaging Director · b. 1976

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue7.52B1.03B373.80M2.46B
Growth (%)--86.31%-63.71%+557.29%
Cost of Revenue2.78B7.46B8.21B7.53B
Gross Profit4.75B-6.43B-7.83B-5.07B
Gross Margin63.10%-624.16%-2095.50%-206.46%
Operating Expense28.04B10.50B11.89B5.26B
Operating Income-23.29B-16.93B-19.72B-10.33B
Operating Margin-309.52%-1643.77%-5275.44%-420.64%
EBITDA-29.47B-9.73B-19.80B-22.02B
EBITDA Margin-391.62%-945.07%-5295.98%-896.24%
Net Income-37.22B-16.99B-26.27B-29.67B
Net Income Margin-494.62%-1649.40%-7027.04%-1207.72%
R&D8.63B4.69B5.14B1.58B
R&D as % of Total Revenue114.76%454.87%1374.93%64.38%
Interest Expense2.47B2.39B1.97B3.25B
Interest Expense % of Total Revenue32.77%232.11%526.26%132.20%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets64.90B67.20B46.65B54.73B
Total Liabilities91.74B31.08B26.17B10.47B
Total Equity-26.84B36.12B20.48B44.26B
Cash333.33M7.31B1.17B9.39B
Net Debt24.19B13.93B16.17B39.38M

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-13.23B-15.84B-12.84B-11.17B
Capital Expenditure2.26B2.20B615.67M4.11B
Free Cash Flow-15.49B-18.03B-13.46B-15.28B
FCF to OCF117.04%113.86%104.79%136.83%

Earnings

Report DateJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------
EPS Actual-904.77-972.52-427.61-998.30-2255.91-897.10-1152.69-377.02-1230.38-573.48-1462.08-595.43-235.59
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap49.08B
Enterprise Value50.16B
Trailing P/E0.00
Forward P/E0.00
Price / Sales44.78
Price / Book1.11
Revenue (TTM)1.10B
Gross Profit (TTM)-6.04B
EBITDA-6.25B
Profit Margin0.00%
Operating Margin-939.23%
Return on Equity-69.96%
Return on Assets-10.23%
Shares Outstanding12.81M
Shares Float71.77M
Beta-0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 1, 20260.111:1